Delivering Innovation to the EyeTM
Focused on developing and commercializing innovative ophthalmic products and technologies for serious ophthalmic diseases
Now Approved!
Who We Are
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.
Our Technology
EyePoint has developed five products approved by the FDA for, sustained-release delivery of drugs to the eye.
Our Pipeline
EyePoint has a number of products in development that utilize our proven DurasertTM and Verisome Technology platforms®.
About EyePoint
Latest EyePoint News
- EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
- EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9%
- EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
- EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
- EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg